Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)
Stopped Because GSK concluded that it was impossible to recruit sufficient participants within a reasonable timeframe.
Conditions
Interventions
- DRUG: Ropinirole immediate release (IR)
- DRUG: Placebo
Sponsor
GlaxoSmithKline